GTBP Monoclonal Antibody

This gene encodes a member of the DNA mismatch repair MutS family. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. Transcripts variants encoding different isoforms have been described.

Introducing the GTBP Monoclonal Antibody, a cutting-edge biotechnological innovation designed to revolutionize the field of cancer diagnostics and therapeutics. This meticulously engineered antibody is specifically developed to target and bind to the GTBP protein, a crucial biomarker associated with various types of cancer.

Crafted with utmost precision and utilizing state-of-the-art molecular biology techniques, the GTBP Monoclonal Antibody exhibits exceptional specificity and affinity towards the GTBP protein, enabling accurate detection and quantification of its presence in biological samples. This groundbreaking antibody offers unparalleled sensitivity, ensuring reliable and precise identification of GTBP protein expression levels, even in low abundance scenarios.

The GTBP Monoclonal Antibody's exceptional performance extends beyond diagnostics, as it also holds immense potential in therapeutic applications. By selectively binding to the GTBP protein, this antibody effectively inhibits its function, thereby impeding cancer cell proliferation and promoting apoptosis. This targeted approach presents a promising avenue for personalized cancer treatment strategies, offering enhanced efficacy and reduced side effects compared to conventional therapies.

Furthermore, the GTBP Monoclonal Antibody boasts exceptional stability and reproducibility, ensuring consistent and reliable results across various experimental conditions. Its compatibility with a wide range of techniques, including immunohistochemistry, flow cytometry, and Western blotting, further enhances its versatility and applicability in diverse research settings.

In summary, the GTBP Monoclonal Antibody represents a groundbreaking advancement in cancer research and treatment. With its exceptional specificity, sensitivity, and therapeutic potential, this innovative antibody is poised to revolutionize the field, empowering researchers and clinicians alike in their quest to combat cancer and improve patient outcomes.